Sweden-based BioInvent International, a drug-development firm, has entered into an agreement with Alligator Bioscience, also a Sweden-based drug-development firm, to provide process development and manufacturing services for Alligator's new bispecific antibody, ADC-1015, for immuno-oncology.

The agreement with Alligator is expected to generate revenues of more than SEK 20 million ($2.35 million) in 2016 to 2018, with the majority of revenues to be generated in 2017. Other financial terms were not disclosed.

Alligator discovers and develops antibody-based immunotherapies for the treatment of metastatic cancer and has a pipeline of five product candidates.

Source: BioInvent